Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Symbol: 300357.SZ
SHZ
25.97
CNYMarket price today
44.2441
P/E Ratio
-6.3048
PEG Ratio
13.60B
MRK Cap
- 0.01%
DIV Yield
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357-SZ) Financial Statements
Balance Sheet
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1288.8 | 1135.7 | 1020.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 117.4 | 295.1 | 370.9 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 214.9 | 284.9 | 256.2 | |||||||||||||||
balance-sheet.row.inventory | 0 | 59 | 48.4 | 53.8 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 7.2 | 8.1 | 10.7 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 1569.9 | 1477.1 | 1341.5 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 704.8 | 444.6 | 301.6 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 188.4 | 189.5 | 176.4 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | -43.2 | -216.7 | -287.6 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 5 | 4.9 | 5.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 137.2 | 298.4 | 394.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 992.3 | 720.7 | 590.5 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 8 | 7.7 | 5.1 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 41.2 | 4 | 5.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 14.5 | 30.3 | 62.9 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
Deferred Revenue Non Current | 0 | 30.9 | 27.4 | 24.9 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 127.5 | 91.1 | 96.6 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 81.4 | 68 | 27.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 21.3 | 12.3 | 1.9 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 258.5 | 170.8 | 135.4 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 523.6 | 523.6 | 523.6 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 1262.6 | 1092.7 | 889.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 270.7 | 235.1 | 194.7 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 128.2 | 128.2 | 128.2 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 2185.1 | 1979.6 | 1736.1 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 2562.2 | 2197.9 | 1932 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 118.6 | 47.5 | 60.5 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 2303.7 | 2027.1 | 1796.6 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 74.2 | 78.4 | 83.3 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 62.4 | 16.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | 0 | -1108.9 | -824.4 | -642.2 |
Cash Flow Statement
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 295.5 | 335.7 | 326.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 38.5 | 26.1 | 25.1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0.5 | -1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | -0.5 | 1 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 47.4 | -47.2 | 11.5 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -30.9 | -34.6 | |||||||||||||||
cash-flows.row.inventory | 0 | -9.4 | 4.1 | -5.4 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | -20.9 | 52.5 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 56.8 | 0.5 | -1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0.7 | 45.7 | -2.3 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0.2 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | -600.1 | -484.4 | -843.1 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 612.2 | 517.6 | 742.7 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 5.1 | 37.1 | 10.2 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -191.9 | -118.2 | -212.3 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | -20 | -5.8 | -5.8 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | -105.6 | -105.2 | -83.8 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 77.2 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -23.4 | -111 | -89.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 166.8 | 131.1 | 58.7 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 577.6 | 410.8 | 279.7 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 410.8 | 279.7 | 221 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 382.1 | 360.3 | 360.6 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | -209.2 | -188.7 | -122.2 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 172.9 | 171.5 | 238.4 |
Income Statement Row
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 848.2 | 896 | 807.7 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 40.2 | 41.3 | 34.4 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 808 | 854.7 | 773.3 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 494.2 | 439.5 | 407.2 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 534.4 | 480.8 | 441.6 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 31 | 24.8 | 22.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1 | 16.1 | 28.5 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1 | 2.5 | 0.1 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.4 | 0.4 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 38.5 | 75.9 | 27.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 345 | 396.2 | 392.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 346 | 398.7 | 393 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 50.4 | 63 | 66.7 | |||||||||||||||
income-statement-row.row.net-income | 0 | 310.2 | 348.8 | 338 |
Frequently Asked Question
What is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) total assets?
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) total assets is 2562166715.000.
What is enterprise annual revenue?
The annual revenue is N/A.
What is firm profit margin?
Firm profit margin is 0.953.
What is company free cash flow?
The free cash flow is 0.312.
What is enterprise net profit margin?
The net profit margin is 0.360.
What is firm total revenue?
The total revenue is 0.392.
What is Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ) net profit (net income)?
The net profit (net income) is 310184878.000.
What is firm total debt?
The total debt is 62443059.000.
What is operating expences number?
The operating expences are 494184515.000.
What is company cash figure?
Enretprise cash is 0.000.